Individualizing Interventions for Cancer Prevention

  • Michael Pollak
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)


Many cancer prevention strategies are unlikely to provide equal risk reduction in all subjects, but instead are predicted to be particularly useful for specific individuals. An important research challenge is to devise methods for individualization of cancer prevention recommendations, such that particular interventions are assigned to those who will gain the most. Research in this area is at an early stage, but progress that allows rational assignment of specific prevention strategies to particular individuals who will benefit would decrease the cost, minimize the toxicity, and increase the efficacy of interventions intended to prevent cancer.


Breast Cancer Risk Cancer Prevention BRCA1 Mutation Natl Cancer Inst Sporadic Breast Cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thompson IM, Goodman PJ, Tangen CM, et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224PubMedCrossRefGoogle Scholar
  2. 2.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Daly M, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  3. 3.
    King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant Breast and Bowel Project (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedGoogle Scholar
  4. 4.
    Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D’Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P, Tamoxifen Study Group (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165PubMedGoogle Scholar
  5. 5.
    Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87: 1622–1629PubMedGoogle Scholar
  6. 6.
    Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J (2000) Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9:911–915PubMedGoogle Scholar
  7. 7.
    Atkinson C, Warren R, Bingham SA, Day NE (1999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8:863–866PubMedGoogle Scholar
  8. 8.
    Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group [see comments]. JAMA 276:1404–1408PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women [see comments]. N Engl J Med 336: 611–617PubMedCrossRefGoogle Scholar
  10. 10.
    Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292–1299PubMedCrossRefGoogle Scholar
  11. 11.
    Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280PubMedCrossRefGoogle Scholar
  12. 12.
    Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55:3973–3975PubMedGoogle Scholar
  13. 13.
    Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R (1990) Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693–1697PubMedGoogle Scholar
  14. 14.
    Torrisi R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C, Decensi A (2000) Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 87: 601–605PubMedCrossRefGoogle Scholar
  15. 15.
    Novelli G, Margiotti K, Sangiuolo F, Reichardt JK (2001) Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2:65–72PubMedCrossRefGoogle Scholar
  16. 16.
    Costantino JP (2001) Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. Ann N YAcad Sci 949: 280–285Google Scholar
  17. 17.
    Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DJ (1997) Circulating and skeletal insulin-like growth factor-I (IGF-1) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21: 217–223PubMedCrossRefGoogle Scholar
  18. 18.
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396PubMedCrossRefGoogle Scholar
  19. 19.
    Pollak M, Blouin MJ, Zhang JC, Kopchick JJ (2001) Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 85:428–430PubMedCrossRefGoogle Scholar
  20. 20.
    Pollak M, Foulkes WD (2003) Challenges to cancer control by screening. Nat Rev Cancer 3:297–303PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Michael Pollak
    • 1
  1. 1.Cancer Prevention CentreMcGill UniversityMontrealCanada

Personalised recommendations